Publication Topic

Suh M, Cloud M, Balasubramanian A, Movva N, Fryzek J, Cohen S. 2022. A systematic literature review (SLR) of MTAP deletions in multiple solid and hematologic cancers. PROSPERO 2022 CRD42022354037.

Lynch HN, Lauer DJ, Thompson WJ, Leleck O, Freid RD, Collins J, Chen K, et al. 2022. Systematic review of the scientific evidence of the pulmonary carcinogenicity of talc. Front Public Health 10:989111; doi: 10.3389/fpubh.2022.989111.

Bylsma L, Fryzek J, Movva N, Frankenfeld C, Hooda N, Pundole X, et al. 2022. Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. PROSPERO 2022 CRD42022351119

Tsvetkov L, Pittsenbarger J, Atsriku C, Devine P, Dingley K, et al. 2022. Inhibition of CDC7 with Sgr-2921 in AML models results in enhanced DNA damage and anti-leukemic activity as monotherapy and in combination with standard of care agents. Blood 140 (Supplement 1):5961–5962; doi: 10.1182/blood-2022-167239.

Tice RR, Bassan A, Amberg A, Anger LT, Beal MA, Bellion P, Benigni R, Birmingham J…, Mihalchik-Burhans AL, et al. 2021. In silico approaches in carcinogenicity hazard assessment: Current status and future needs. Comp Toxicol 20(Nov):100191; doi: 10.1016/j.comtox.2021.100191.

Hackshaw A, Cohen SS, Reichert H, Kansal AR, Chung KC, Ofman JJ. 2021. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. Brit J Cancer, open access.

Yin W, Nie Z, Dingley K, Trzoss M, Krilov G, Marshall N et al. 2021. Characterization of potent paracaspase MALT1 inhibitors for hematological malignancies. Blood 138 (Supplement 1):1187; doi: 10.1182/blood-2021-153159.

Proctor DM, Bhat V, Suh M, Reichert H, Jiang X, Thompson CM. 2021. Inhalation cancer risk assessment for environmental exposure to hexavalent chromium: Comparison of margin-of-exposure and linear extrapolation approaches. Regul Toxicol Pharmacol 124(August):104969; doi: 10.1016/j.yrtph.2021.104969.

Alexander DD, Pastula ST, Riordan AS. 2021. Epidemiology of lung cancer among acrylonitrile-exposed study populations: A meta-analysis. Regul Toxicol Pharmacol 122(June):104896; doi: 10.1016/j.yrtph.2021.104896. PMID: 33617939.

Bylsma L, Nielson C, Fryzek J, Saad H, Crawford J. Edit chemotherapy relative dose intensity, overall survival, and hematologic toxicity in solid-tumor cancer patients: A literature review and meta-analysis. Poster presentation [preview] at 37^th ICPE (International Conference on Pharmacoepidemiology & Therapeutic Rick Management), Virtual, August 2021.

Ierardi AM, Lotter JT, Jacobs N, Finley BL, Pierce JS. Derivation of a proposed asbestiform tremolite NOAEL for lung cancer. Virtual poster Presentation at Society of Toxicology 60^th Annual Meeting, Virtual, 2021.

Levin-Sparenberg E, Bylsma LC, Lowe K, Sangare L, Fryzek JP, Alexander DD. 2020. A systematic literature review and meta-analysis describing the prevalence of KRAS, NRAS, and BRAF gene mutations in metastatic colorectal cancer. Gastroenterol Res 13(5):184–198; doi: 10.14740/gr1167.

Cohen S, Reichert H, Kansal AR, Chung KC. Improved efficiency of cancer screening with multi-cancer early detection test. International Society for Pharmacoeconomics and Outcomes Research, Inc. (ISPOR) Virtual Conference, May 2020.

Bylsma LC, Gillezeau C, Garawin TA, Kelsh MA, Fryzek JP, Sangaré L, et al. 2020. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med 9(3):1044–1057.

Li S, Liu J, Gong T, Guo H, Gawade PL, Kelsh MA, et al. 2020. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. J Geriatr Oncol 11(8):1309–1315.

Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA, et al. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. 2020. Curr Med Res Opin 36(9):1519–1527.

Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. 2020. Support Care Cancer 28(9):4413–4424.

Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA. 2020. A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. J Cancer Edu 35(1):178–186.

Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA, et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478.

Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, … Kelsh M, et al. 2020. Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871–e882.